804 results on '"Colucci M"'
Search Results
2. Nuclear physics midterm plan at Legnaro National Laboratories (LNL)
3. Case Report: An unusual case of a transposition of the great arteries with a double aortic arch: a highly complex fetal diagnosis with an unpredictable outcome
4. Structure-property relationship of scintillating garnet optical ceramics towards effective radiation detection schemes
5. 123P A phase II study of nivolumab (N) plus ipilimumab (I) and ASTX727 or N plus I in PD-1/PD-L1 resistant melanoma or NSCLC patients: The run-in phase of the NIBIT Foundation ML1 study
6. 113P A multidisciplinary management of immune-checkpoint inhibitor (ICI)-related pneumonitis to improve its clinical management
7. Research on Emerging Medical radionuclides from the X-sections (REMIX): The Accelerator-based Production of 47Sc, 149Tb, 152Tb, 155Tb and 161Tb
8. Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin‐independent impairment of the thrombin‐activatable fibrinolysis inhibitor pathway
9. Consecutive episodes of heart and kidney failure in an “otherwise” healthy young man
10. Multi-population genome-wide association study implicates immune and non-immune factors in pediatric steroid-sensitive nephrotic syndrome.
11. Assessing consumers’ propensity towards products-service systems in the fashion industry – A cross-national comparison between Russia and Italy.
12. Role of sintering aids in the photo-physical properties of GGAG:Ce scintillating optical ceramics
13. A phase I study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndrome
14. Covid-19 specific immune markers revealed by single cell phenotypic profiling
15. Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin‐activatable fibrinolysis inhibitor but not the anti‐inflammatory activity on osteopontin and C5a
16. LBA47 Nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Primary analysis of the randomized phase II NIBIT-ML1 study
17. Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI‐mediated inhibition of fibrinolysis
18. Italian projects to educate, train and bring the young generation to discover the radioactivity
19. Erhöhte Anlagenverfügbarkeit durch die Integration von Industrie 4.0-fähigen Messgeräten in Cloud-basierte Asset Health-Applikationen
20. Evaluation of immediate impact of cane use on energy expenditure during gait in patients with knee osteoarthritis
21. Genuine representation of brands: a new method of representing unbiased brand-by-attribute perceptions
22. Expansion of CD4dimCD8+ T cells characterizes macrophage activation syndrome and other secondary HLH
23. Aplicación de la separación celular para la identificación de factores de riesgo genético en mieloma múltiple: un estudio de la vida real
24. The role of thrombin activatable fibrinolysis inhibitor and factor XI in platelet‐mediated fibrinolysis resistance: a thromboelastographic study in whole blood
25. Terbium radionuclides production by deuteron beams irradiation for medical applications
26. Training School MERADE MEasurements of RADioactivity in the Environment
27. The REMIX Project: Early Results on the Determination of the XS for the Production of Theranostic-Relevant Isotopes of Terbium by Deuteron Irradiation of Dysprosium Foils
28. Co-circulation of SARS-CoV-2 Alpha and Gamma variants in Italy, February and March 2021
29. Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer
30. Research on Emerging Medical radionuclides from the X-sections (REMIX): The Accelerator-based Production of 47Sc, 149Tb, 152Tb, 155Tb and 161Tb
31. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin‐activatable fibrinolysis inhibitor
32. Dabigatran but not rivaroxaban or apixaban reduces fibrinolytic resistance in patients with atrial fibrillation: OR065
33. Mild hyperhomocysteinemia is associated with increased TAFI levels and reduced plasma fibrinolytic potential
34. 'Activate your Wait' project : pilot study carried out at a thermal centre ['Attiva l’attesa': Studio pilota presso uno stabilimento termale]
35. Use of autopsy findings in evaluation of evidence collected during crime scene investigation to detect a staging in a case of work-related fatality
36. Leadership in Public Health: Opportunities for Young Generations Within Scientific Associations and the Experience of the “Academy of Young Leaders”
37. Erice 2018 Charter on the role of the National Health Service in the prevention of doping
38. From discovery to growth. Foreign immigration in Campania from 1970s to 1990s|Dalla scoperta alla crescita. L'immigrazione straniera in campania dagli anni settanta agli anni novanta
39. RISCHI PER LA SALUTE ASSOCIATI CON LE PRATICHE DI ORNAMENTO CORPOREO: CONOSCENZE ED ESPERIENZE DI UN CAMPIONE DI STUDENTI UNIVERSITARI
40. Dal tribalismo urbano alla marginalità avanzata
41. Associations between allelic variants of the human IgH 3′ regulatory region 1 and the immune response to BNT162b2 mRNA vaccine
42. FIX-Padua increases fibrinolytic resistance through a TAFI-mediated mechanism: PB 2.72–1
43. Differential stimulation of fibrinolysis by vitamin K-antagonists alone and associated with lowmolecular-weight heparin: PB 1.45–2
44. Characterization of two monoclonal antibodies that inhibit the antifibrinolytic but not the antiinflammatory activity of activated TAFI: OC 84.5
45. EP09.84: Ventricular disproportion in prenatal diagnosis of coarctation of the aorta: impact of ventricular deptal defect on diagnosis.
46. EP09.38: Placental pathology in pregnancies complicated by right heart obstructive lesions.
47. OP04.03: Placental vascular malperfusion in fetuses with congenital heart diseases: distinction based on pathophysiology.
48. Factors associated with access to antiviral treatment in a multicentre cross-sectional study of patients with chronic hepatitis B in Italy
49. More on the effect of oral anticoagulant treatment on TAFI/TAFIa levels and clot resistance to fibrinolysis: O3.6.05
50. Decreased fibrinolytic resistance of plasma clots containing red blood cells: O3.8.02
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.